Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 196

1.

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.

Larocca A, Mina R, Offidani M, Liberati AM, Ledda A, Patriarca F, Evangelista A, Spada S, Benevolo G, Oddolo D, Innao V, Cangialosi C, Bernardini A, Musto P, Amico V, Fraticelli V, Paris L, Giuliani N, Falcone AP, Zambello R, De Paoli L, Romano A, Palumbo A, Montefusco V, Hajek R, Boccadoro M, Bringhen S.

Haematologica. 2019 Jun 27. pii: haematol.2019.220657. doi: 10.3324/haematol.2019.220657. [Epub ahead of print]

2.

Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, Dimopoulos MA, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV.

Ann Hematol. 2019 Jun 25. doi: 10.1007/s00277-019-03739-2. [Epub ahead of print]

PMID:
31240472
3.

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.

Montefusco V, Gay F, Spada S, De Paoli L, Di Raimondo F, Ribolla R, Musolino C, Patriarca F, Musto P, Galieni P, Ballanti S, Nozzoli C, Cascavilla N, Ben-Yehuda D, Nagler A, Hajek R, Offidani M, Liberati AM, Sonneveld P, Cavo M, Corradini P, Boccadoro M.

Haematologica. 2019 Jun 20. pii: haematol.2019.219139. doi: 10.3324/haematol.2019.219139. [Epub ahead of print]

4.

Extramedullary disease in multiple myeloma - controversies and future directions.

Sevcikova S, Minarik J, Stork M, Jelinek T, Pour L, Hajek R.

Blood Rev. 2019 Jul;36:32-39. doi: 10.1016/j.blre.2019.04.002. Epub 2019 Apr 13. Review.

5.

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J.

Blood. 2019 May 2;133(18):1953-1963. doi: 10.1182/blood-2018-09-874396. Epub 2019 Feb 28.

PMID:
30819926
6.

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Ludwig H, Moreau P, Dimopoulos MA, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K.

Blood Cancer J. 2019 Feb 22;9(3):23. doi: 10.1038/s41408-019-0181-0.

7.

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.

Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Jul;33(7):1817-1821. doi: 10.1038/s41375-019-0396-x. Epub 2019 Feb 8. No abstract available.

PMID:
30737484
8.

Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making.

Gonzalez-McQuire S, Dimopoulos MA, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S.

MDM Policy Pract. 2019 Jan 17;4(1):2381468318814253. doi: 10.1177/2381468318814253. eCollection 2019 Jan-Jun.

9.

Long Non-Coding RNAs in Multiple Myeloma.

Butova R, Vychytilova-Faltejskova P, Souckova A, Sevcikova S, Hajek R.

Noncoding RNA. 2019 Jan 24;5(1). pii: E13. doi: 10.3390/ncrna5010013. Review.

10.

CD38 targeted treatment for multiple myeloma.

Jelínek T, Mihályová J, Hájek R.

Vnitr Lek. Fall 2018;64(10):939-948.

PMID:
30590941
11.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
12.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922
13.

Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.

Jelinek T, Paiva B, Hajek R.

Front Immunol. 2018 Nov 16;9:2431. doi: 10.3389/fimmu.2018.02431. eCollection 2018. Review.

14.

Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project.

Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, Turesson I, Lahuerta JJ, Attal M, Barlogie B, Lee JH, Kumar S, Lenhoff S, Morgan G, Rajkumar SV, Durie BGM, Moreau P.

Blood Cancer J. 2018 Nov 23;8(12):123. doi: 10.1038/s41408-018-0155-7.

15.

Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma.

Jelinek T, Adamusova L, Popkova T, Tvrda I, Smejkalova J, Simicek M, Salounova D, Kascak M, Mihalyova J, Plonkova H, Duras J, Navratil M, Hajek R, Koristek Z.

Bone Marrow Transplant. 2019 Jul;54(7):1107-1114. doi: 10.1038/s41409-018-0396-x. Epub 2018 Nov 20.

PMID:
30459429
16.

Selected Genetic Polymorphisms Associated with Hypoxia and Multidrug Resistance in Monoclonal Gammopathies Patients.

Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlíček P, Roziakova L, Penka M, Hájek R, Vasku A, Sevcikova S.

Klin Onkol. Spring 2018;31(3):213-229. doi: 10.14735/amko2018213.

PMID:
30441975
17.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC.

Blood Cancer J. 2018 Nov 9;8(11):109. doi: 10.1038/s41408-018-0141-0. Review.

18.

Single agent daratumumab in advanced multiple myeloma possesses significant efficacy even in an unselected "real-world" population.

Minarik J, Pour L, Maisnar V, Spicka I, Jungova A, Jelinek T, Brozova L, Krhovska P, Scudla V, Hajek R.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Nov 6. doi: 10.5507/bp.2018.064. [Epub ahead of print]

PMID:
30397362
19.

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).

Jelinek T, Mihalyova J, Kascak M, Duras J, Popkova T, Benkova K, Richterova P, Plonkova H, Zuchnicka J, Broskevicova L, Huvarova L, Cerna L, Growkova K, Simicek M, Havel M, Gumulec J, Navratil M, Koristek Z, Paiva B, Hajek R.

Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25. No abstract available.

PMID:
30370955
20.

From open packing to negative wound pressure therapy: A critical overview of deep sternal wound infection treatment strategies after cardiac surgery.

Simek M, Chudoba A, Hajek R, Tobbia P, Molitor M, Nemec P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 Sep 14. doi: 10.5507/bp.2018.053. [Epub ahead of print]

PMID:
30215435

Supplemental Content

Loading ...
Support Center